Still’s disease is a serious orphan disease caused by a deregulation of the immune system triggering an acute inflammatory response. Under the auspices of UNIGE and HUG, an international team has successfully tested a molecule inhibitor of interleukin-18, a protein involved in immune response. These encouraging results in terms of safety and efficacy are paving the way for a new kind of treatment, not only for Still’s disease, but other rare inflammatory diseases, too.

This post comes from the RSS feed of EurekaAlert, you can find more here!

Written by admin